CD274 and breast cancer: Inhibiting these pathways, in conjunction with anti-PD-L1 therapy, robustly enhances antitumor responses in mouse models of melanoma, lung, and breast cancer (BC), supporting a dual-target strategy against T cell senescence and exhaustion to potentiate cancer immunotherapy [44].